Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis
Annals of Oncology, Volume 23, No. 5, Year 2012
Notification
URL copied to clipboard!
Description
Background: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor with the ability to increase progression-free survival in metastatic breast cancer (MBC). A systematic review and meta-analysis was conducted to determine the risk of the most clinically relevant adverse outcomes associated with the use of bevacizumab in the treatment of breast cancer. Patients and methods: We included phase III clinical trials that used bevacizumab alone or in combination with chemotherapy as for MBC or locally recurrent. Statistical analyses were conducted to calculate summary odds ratio (OR) of the eight most relevant adverse outcomes related with bevacizumab. Results: Five clinical trials were included in the meta-analysis. Summary odds ratios obtained showed a statistically significant bevacizumab-associated increased risk in four of the adverse outcomes studied: proteinuria (OR = 27.68), hypertension (OR = 12.76), left ventricular dysfunction (LVD) (OR = 2.25), and hemorrhagic events (OR = 4.07). No statistically significant differences were found for gastrointestinal (GI) perforation, vascular events, fatal events, or febrile neutropenia. Conclusions: Bevacizumab did increase the risk of LVD and hemorrhagic events. The addition of bevacizumab to chemotherapy in patients with metastatic breast cancer was not associated with a significant increase in grade ≥3 arterial or venous thromboembolic events, GI perforation, or fatal events. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Authors & Co-Authors
Corteś, Javier O.
Spain, Barcelona
Hospital Universitari Vall D'hebron
Calvo, V.
Spain, Madrid
Hospital Universitario Ramón y Cajal
Ramírez-Merino, N.
Spain, Guadalajara
Hospital Universitario de Guadalajara
O'Shaughnessy, Joyce Ann
United States, Dallas
Baylor Charles A. Sammons Cancer Center
Brufsky, Adam M.
United States, Pittsburgh
University of Pittsburgh Medical Center
Robert, Nicholas J.
Unknown Affiliation
Vidal, M.
Spain, Barcelona
Hospital Universitari Vall D'hebron
Muñoz, E.
Spain, Barcelona
Hospital Universitari Vall D'hebron
Perez, J.
Spain, Barcelona
Hospital Universitari Vall D'hebron
Dawood, Shaheenah S.
United Arab Emirates, Dubai
Dubai Health Authority
Saura, Cristina
Spain, Barcelona
Hospital Universitari Vall D'hebron
Di Cosimo, Serena
Spain, Barcelona
Hospital Universitari Vall D'hebron
González Martín, Antonio J.
Spain, Madrid
Md Anderson Cancer Center, Madrid
Bellet, Meritxell
Spain, Barcelona
Hospital Universitari Vall D'hebron
Silva, O. E.
United States, Miami
University of Miami Leonard M. Miller School of Medicine
Miles, David W.
United Kingdom, Stevenage
East and North Hertfordshire Nhs Trust
Llombart-Cussac, Antonio C.
Spain, Valencia
Hospital Arnau de Vilanova
Baselga, José M.
United States, Boston
Massachusetts General Hospital
Statistics
Citations: 63
Authors: 18
Affiliations: 11
Identifiers
Doi:
10.1093/annonc/mdr432
ISSN:
09237534
e-ISSN:
15698041
Research Areas
Cancer
Noncommunicable Diseases
Study Design
Case-Control Study
Study Approach
Systematic review